ArticleBone marrow transplantation2021
Extra-medullary recurrence of myeloid leukemia as myeloid sarcoma after allogeneic stem cell transplantation: impact of conditioning intensity.
Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Clinical and Molecular Characterization of Myeloid Sarcoma: A Systematic Review and Meta-Analysis.Cancers · 2025Review
- Acute Myeloid Leukemia With Extramedullary Infiltration-Gastric Myeloid Sarcoma: A Case Report and Literature Review.Clinical case reports · 2025Article
- Diagnostic Approaches in Myeloid Sarcoma.Current issues in molecular biology · 2025Review
- Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma.Discover oncology · 2024Article
- Intracranial Myeloid Sarcoma Mimicking Hypertensive Intracerebral Hemorrhage.Internal medicine (Tokyo, Japan) · 2023Article
- Myeloid sarcoma: more and less than a distinct entity.Annals of hematology · 2023Review
- Pediatric Myeloid Sarcoma, More than Just a Chloroma: A Review of Clinical Presentations, Significance, and Biology.Cancers · 2023Review
- Case report: The first case of concurrent breast myeloid sarcoma and borderline phyllodes tumor with malignant features.Frontiers in oncology · 2023Article
- Myeloid sarcoma with ulnar nerve entrapment: A case report.World journal of clinical cases · 2022Article
- Clinical characteristics, treatment, and prognosis of 118 cases of myeloid sarcoma.Scientific reports · 2022Article
- Leukaemic Ascites and Peritoneal Myeloid Sarcoma: Rare but Not Impossible.European journal of case reports in internal medicine · 2022Article
- Review
- Extramedullary acute myeloid leukemia (eAML): Retrospective single center cohort study on clinico-pathological, molecular analysis and survival outcomes.Annals of medicine and surgery (2012) · 2021Article
- Clinical and molecular characterization of myeloid sarcoma without medullary leukemia.Leukemia & lymphoma · 2021Article
- Post-transplant relapse of therapy-related MDS as gastric myeloid sarcoma: Case report and review of literature.Leukemia research reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid sarcoma (MS) as a solid extra-medullary (EM) manifestation of acute myeloid leukemia (AML), myeloproliferative or myelodysplastic syndromes is a rare presentation of relapse after allogeneic hematopoietic stem cell transplantation (HSCT). The databases of the Departments of Hematology and Oncology of the University Hospitals of Jena and Rostock were screened for patients aged 18 years or older for onset of MS after HSCT for myeloid malignancies between 2002 and 2019. Nineteen patients with MS were identified, the majority of whom had received reduced-intensity conditioning (RIC). The median onset of MS was 425 days after HSCT and the median overall survival since MS was 234 days. Although MS is associated with a poor prognosis, three patients survived more than two years and one more than 11 years after MS onset. These results indicate that RIC protocols may be associated with a higher risk of EM relapse. Since EM relapse occurred in the presence of Graft-versus-host-disease, these observations also demonstrate the limitations of graft-versus-tumor effects after HSCT. In conclusion, occurrence of MS after HSCT is associated with a poor prognosis, as multimodal curative concepts including intensive chemotherapy and another HSCT are often not viable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.